Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corcept Therapeutics Inc CORT

Healthcare
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has... see more

Recent & Breaking News (NDAQ:CORT)

Corcept Shareholder Alert

Newsfile January 7, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

PR Newswire January 6, 2022

Corcept Shareholder Alert

Newsfile January 5, 2022

Corcept Investor Alert

Newsfile January 4, 2022

Corcept Shareholder Notice

Newsfile January 2, 2022

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer

GlobeNewswire December 20, 2021

Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer

GlobeNewswire December 16, 2021

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

GlobeNewswire December 15, 2021

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm

Business Wire December 14, 2021

Corcept Investor Alert

Newsfile December 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

PR Newswire December 13, 2021

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

GlobeNewswire December 8, 2021

Corcept Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 10, 2021

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock

GlobeNewswire November 8, 2021

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

GlobeNewswire November 3, 2021

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

GlobeNewswire October 27, 2021

Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm

Newsfile October 4, 2021

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

GlobeNewswire September 17, 2021

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021

GlobeNewswire September 9, 2021

Weakness In Corcept Shares Is 'Overdone,' According To Analyst

Benzinga.com  October 10, 2017